Novo Nordisk says it is increasing its full-year outlook for 2026 after strong demand for its weight-loss treatment Wegovy. Both outlets report that Wegovy has surpassed 5 million prescriptions in the United States since it first launched, indicating continued momentum in a key market. Quartz adds that the company’s profit is tracking higher than expected, linking the improved performance to the scale of U.S. prescribing. Free Malaysia Today similarly attributes the updated forecast to Wegovy’s success, noting early uptake beyond the United States as well. The reports do not provide additional quantitative detail on international prescription levels or specify the exact financial figures behind the revised guidance. Overall, the coverage centers on the same development: Novo Nordisk’s revised outlook is driven by sustained sales of Wegovy, supported by cumulative U.S. prescriptions exceeding five million and signs of broader international adoption.